Resources Library

For decades, clinical development leaders in US and Europe have viewed China primarily through a logistical lens: a large patient pool capable of accelerating trial enrolment. However, the industry dynamics are shifting. China has evolved from a destination for increased patient access into a source of novel biomedical innovation [Clinical Leader, 2021], [Armstrong, 2026]. Executives leading biopharmas, CROs and CDMOs must adapt to this transformation to facilitate a bi-directional flow of cross-border innovation.

FDA’s 2026 draft guidance quietly rewrites the rules for how Bayesian methods can drive—not just decorate—primary efficacy decisions in drug and biologic trials, but sponsors still face major friction around priors, simulation burden, and documentation expectations (Ji, 2026; U.S. Food and Drug Administration, 2026a; Applied Clinical Trials, 2026).